Multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation prior to conventional dose radiotherapy for clinically localized prostate cancer

被引：0
|
作者：
Crook, JM
Ludgate, C
Lim, J
Malone, S
Eapen, L
Perry, G
Bowen, J
Robertson, S
Lockwood, G
机构：
来源：
JOURNAL OF UROLOGY | 2004年 / 171卷 / 04期
关键词：
D O I：
10.1016/S0022-5347(18)38419-2
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [41] Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer - Editorial comment
    Garnick, MB
    JOURNAL OF UROLOGY, 1996, 155 (01): : 212 - 212
  • [42] Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial.
    Nabid, Abdenour
    Garant, Marie-Pierre
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Lemaire, Celine
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Carrier, Nathalie
    Duclos, Marie
    Souhami, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Randomized Phase 3 Trial of Adjuvant Androgen Deprivation in Combination With High-Dose Conformal Radiation Therapy in Intermediate- and High-Risk Localized Prostate Cancer
    Zapatero, A.
    Guerrero, A.
    Maldonado, J.
    Alvarez, A.
    Gonzalez San Segundo, C.
    Cabeza Rodriguez, M.
    Macias, V.
    Pedro-Olive, A.
    Casas, F.
    Boladeras, A.
    Martin de Vidales, C.
    Vazquez de la Torre, M.
    Calvo, F. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S1 - S1
  • [44] Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-Results of the randomized EORTC Phase III trial 22961
    Bolla, M.
    van Tienhoven, G.
    de Reijke, T. M.
    van den Bergh, A. C.
    van der Meijden, A. P.
    Poortmans, P. M.
    Gez, E.
    Kil, P.
    Pierart, M.
    Collette, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
    Parker, Chris C.
    Clarke, Noel W.
    Cook, Adrian
    Kynaston, Howard
    Catton, Charles N.
    Cross, William R.
    Petersen, Peter M.
    Persad, Rajendra A.
    Saad, Fred
    Bower, Lorna C.
    Logue, John
    Payne, Heather
    Forcat, Silvia
    Goldstein, Cindy
    Murphy, Claire
    Anderson, Juliette
    Barkati, Maroie
    Bottomley, David M.
    Branagan, Jennifer
    Choudhury, Ananya
    Chung, Peter W. M.
    Cogley, Lyn
    Goh, Chee L.
    Hoskin, Peter
    Khoo, Vincent
    Malone, Shawn C.
    Masters, Lindsey
    Morris, Stephen L.
    Nabid, Abdenour
    Ong, Aldrich
    Raman, Rakesh
    Tarver, Kathryn L.
    Tree, Alison C.
    Worlding, Jane
    Wylie, James P.
    Zarkar, Anjali M.
    Parulekar, Wendy R.
    Parmar, Mahesh K. B.
    Sydes, Matthew R.
    LANCET, 2024, 403 (10442): : 2405 - 2415
  • [46] Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial
    McKay, Rana R.
    Xie, Wanling
    Yang, Xiaoyu
    Rathkopf, Dana E.
    Laudone, Vincent Paul
    Bubley, Glenn
    Einstein, David Johnson
    Chang, Peter
    Wagner, Andrew
    Kane, Christopher J.
    Parsons, J. Kellogg
    Preston, Mark A.
    Kilbridge, Kerry L.
    Chang, Steven Lee
    Choudhury, Atish Dipankar
    Quoc-Dien Trinh
    Pomerantz, Mark
    Kibel, Adam S.
    Taplin, Mary Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Biochemical relapse-free survival after high dose external radiotherapy (≥78Gy) and 6 months of androgen deprivation in high-risk localized prostate cancer patients
    Reuther, A
    Reddy, C
    Mahadevan, A
    Kupelian, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S289 - S290
  • [48] Update of the results of the Dutch multicenter randomized phase III trial comparing 68 Gy of external beam radiotherapy with 78 Gy for localized prostate cancer
    Al-Mamgani, A.
    van Putten, W. L. J.
    Heemsbergen, W. D.
    Hoogeman, M. S.
    Slot, A.
    Dielwart, M. F. H.
    Lebesque, J. V.
    Incrocci, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 279 - 279
  • [49] Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).
    Williams, Scott
    Davis, Ian D.
    Sweeney, Christopher
    Stockler, Martin R.
    Martin, Andrew James
    Hague, Wendy
    Coskinas, Xanthi
    Yip, Sonia
    Tu, Emily
    Lawrence, Nicola Jane
    Nayar, Namrata
    McDermott, Ray
    Kelly, Paul
    Deignan, Olwyn
    Hughes, Simon
    Fonteyne, Valerie
    Tombal, Bertrand F.
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [50] Long-term vs. Short-term Androgen Deprivation Combined with High-dose Radiotherapy for Intermediate and High-risk Prostate Cancer: Preliminary Results of a GICOR Phase III Randomized Trial
    Zapatero, A.
    Guerrero, A.
    Maldonado, X.
    Alvarez, A.
    Cabeza, A.
    Gonzalez San Segundo, C.
    Macias, V.
    Casas, F.
    Pedro-Olive, A.
    Boladeras, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S40 - S40
12345